Hubra Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 04-12-2024
- Paid Up Capital ₹ 4.85 M
as on 04-12-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.56 Cr
as on 04-12-2024
- Satisfied Charges ₹ 1.00 Cr
as on 04-12-2024
- Revenue 48.09%
(FY 2022)
- Profit 99.83%
(FY 2022)
- Ebitda 107.82%
(FY 2022)
- Net Worth 23.31%
(FY 2022)
- Total Assets 13.71%
(FY 2022)
About Hubra Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.85 M.
The company currently has active open charges totaling ₹2.56 Cr. The company has closed loans amounting to ₹1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pondavakkam Arunagirinathan, Pondavakkam Arunodhayan, and Pondahavakkam Priya serve as directors at the Company.
- CIN/LLPIN
U74900TN2016PTC104726
- Company No.
104726
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Hubra Pharmaceuticals Private Limited offer?
Hubra Pharmaceuticals Private Limited offers a wide range of products and services, including Medical Supplies, Freight Forwarding Services, Consolidation Services.
Who are the key members and board of directors at Hubra Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pondavakkam Arunagirinathan  | Director | 17-Mar-2016 | Current |
| Pondavakkam Arunodhayan | Additional Director | 21-Apr-2016 | Current |
| Pondahavakkam Priya | Director | 17-Mar-2016 | Current |
Financial Performance of Hubra Pharmaceuticals.
Hubra Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 48.09% increase. The company also saw a substantial improvement in profitability, with a 99.83% increase in profit. The company's net worth Soared by an impressive increase of 23.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hubra Pharmaceuticals?
In 2021, Hubra Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mokksha Management Services Private LimitedActive 11 years 2 monthsPondavakkam Arunodhayan and Pondahavakkam Priya are mutual person
3G Surgical Industries Private LimitedActive 5 years 11 monthsPondavakkam Arunodhayan and Pondahavakkam Priya are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 15 Dec 2020 | ₹2.56 Cr | Open |
Indian Overseas Bank Creation Date: 17 Sep 2018 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Hubra Pharmaceuticals?
Hubra Pharmaceuticals has a workforce of 20 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hubra Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hubra Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
